Company / R&D Expense
BioRestorative Therapies, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$10.1M
FY2025
5-year range
$729.1K / $10.1M
FY2021-FY2025
Trend
+150.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $729,058 in FY2021 to $10M in FY2025.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +42.4%.
Improved from $4M to $10M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +42.2%
- 5-Year CAGR
- +42.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +42.4%, indicating consistent growth.
- In FY2025, r&d expense increased 150.2% year-over-year.
- Lowest r&d expense in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.1M | +150.2% |
| FY2024 | $4.0M | +0.0% |
| FY2023 | $4.0M | +14.8% |
| FY2022 | $3.5M | +381.9% |
| FY2021 | $729.1K | -57.7% |
| FY2020 | $1.7M | +13.8% |
| FY2019 | $1.5M | -29.7% |
| FY2018 | $2.2M | -25.4% |
| FY2017 | $2.9M | +37.0% |
| FY2016 | $2.1M | +47.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026